| 000 | 01881 a2200541 4500 | ||
|---|---|---|---|
| 005 | 20250513145322.0 | ||
| 264 | 0 | _c19980921 | |
| 008 | 199809s 0 0 eng d | ||
| 022 | _a1420-4096 | ||
| 024 | 7 |
_a10.1159/000025845 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aHaas, M | |
| 245 | 0 | 0 |
_aAngiotensin-converting enzyme gene polymorphism determines the antiproteinuric and systemic hemodynamic effect of enalapril in patients with proteinuric renal disease. Austrian Study Group of the Effects of Enalapril Treatment in Proteinuric Renal Disease. _h[electronic resource] |
| 260 |
_bKidney & blood pressure research _c1998 |
||
| 300 |
_a66-9 p. _bdigital |
||
| 500 | _aPublication Type: Comparative Study; Journal Article; Research Support, Non-U.S. Gov't | ||
| 650 | 0 | 4 | _aAdult |
| 650 | 0 | 4 |
_aAngiotensin-Converting Enzyme Inhibitors _xtherapeutic use |
| 650 | 0 | 4 |
_aCreatinine _xmetabolism |
| 650 | 0 | 4 |
_aDNA _xanalysis |
| 650 | 0 | 4 |
_aEnalapril _xtherapeutic use |
| 650 | 0 | 4 | _aFemale |
| 650 | 0 | 4 | _aFollow-Up Studies |
| 650 | 0 | 4 | _aGenotype |
| 650 | 0 | 4 |
_aHemodynamics _xdrug effects |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 | _aMale |
| 650 | 0 | 4 | _aMiddle Aged |
| 650 | 0 | 4 |
_aPeptidyl-Dipeptidase A _xdrug effects |
| 650 | 0 | 4 | _aPolymerase Chain Reaction |
| 650 | 0 | 4 | _aPolymorphism, Genetic |
| 650 | 0 | 4 | _aProspective Studies |
| 650 | 0 | 4 |
_aProteinuria _xdrug therapy |
| 650 | 0 | 4 |
_aSodium _xurine |
| 650 | 0 | 4 | _aTreatment Outcome |
| 700 | 1 | _aYilmaz, N | |
| 700 | 1 | _aSchmidt, A | |
| 700 | 1 | _aNeyer, U | |
| 700 | 1 | _aArneitz, K | |
| 700 | 1 | _aStummvoll, H K | |
| 700 | 1 | _aWallner, M | |
| 700 | 1 | _aAuinger, M | |
| 700 | 1 | _aArias, I | |
| 700 | 1 | _aSchneider, B | |
| 700 | 1 | _aMayer, G | |
| 773 | 0 |
_tKidney & blood pressure research _gvol. 21 _gno. 1 _gp. 66-9 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1159/000025845 _zAvailable from publisher's website |
| 999 |
_c9627181 _d9627181 |
||